At the beginning of February, representatives of the Jazz Pharmaceuticals Plc announced the acquisition of the GW Pharmaceuticals Plc for $7.2 billion in cash and stock.
GW, based in Cambridge, England, is currently the only real “cannabis-pharmaceutical” company in the world that develops approved drugs derived from the cannabis plant. Jazz Pharma is a giant in the market for conventional pharmaceuticals, with focus on neurological and oncological diseases.
Deal-making is in full-swing again in the cannabis industry.
Both cannabinoid preparations produced by GW are designed for patients with neurological problems – Sativex (based on THC/CBD) is used for the treatment of multiple sclerosis, while Epidiolex (based on CBD) is used for children with severe epilepsy.
Deal-making is in full-swing again in the cannabis industry: in December, two of the biggest players, Tilray Inc. and Aphria Inc., agreed to combine in a deal valued at $3.8 billion.
Author: Bob Hýsek
Source: Cannabis Therapy Vol. 2
Take a quick look at this preview of the contents:
Feel free to read, share and download here. Enjoy!
